$0.41
(1.78%)
Add to watchlist
Create an alert
Stocks and Shares ISAMonte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Company Information
About this company
Key people
Markus Warmuth
President, Chief Executive Officer, Director
Jennifer Champoux
Chief Operating Officer
Sharon Townson
Chief Scientific Officer
Filip Janku
Chief Medical Officer
Philip Nickson
Chief Business and Legal Officer
Andrew N. Schiff
Non-Executive Independent Chairman of the Board
Ali Behbahani
Independent Director
Kimberly L. Blackwell
Independent Director
Eric A. Hughes
Independent Director
Chandra P. Leo
Independent Director
Click to see more
Key facts
- Shares in issue72.92m
- EPICGLUE
- ISINUS61225M1027
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.77bn
- Employees147
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.